GO-4305C
Metastatic cancers, including BRCA-associated pancreatic ductal adenocarcinoma
Phase 1Active
Key Facts
Indication
Metastatic cancers, including BRCA-associated pancreatic ductal adenocarcinoma
Phase
Phase 1
Status
Active
Company
About General Oncology
General Oncology is an emerging biotech focused on metastatic cancers with high unmet need, originating from a compelling n-of-1 case of a BRCA2+ pancreatic cancer patient treated successfully with melphalan. The company's lead asset, GO-4305C, reported a median progression-free survival of 14.2 months in a 12-patient Phase 1 trial (SHARON) in stage IV BRCA-associated pancreatic ductal adenocarcinoma, with two patients remaining disease-free for over 2.5 years. With a preclinical ophthalmology program in development and a lean team, the company is advancing its novel, multi-modal therapeutic approach while seeking to validate its platform in larger studies.
View full company profile